Great Basin Announces Commercial Launch of Shiga Toxin Direct Test

Customer Evaluations began in July fifty percent customer penetration expected within five to seven months with customer volume estimates ahead of plan for the Company’s molecular test detecting Shiga toxin-producing E. coli and the deadly O157 serotype

Salt Lake City, August 2, 2016 – Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, announced today the commercial launch of its Shiga Toxin Direct Test, the only stand-alone test to provide the Center for Disease Control’s (CDC) recommended identification of the high-virulence serotype O157 in conjunction with detecting Shiga toxin- producing Escherichia Coli, or STEC, giving clinicians definitive patient diagnosis to make timely decisions on the right course of treatment. The Company reports it began evaluations at sites in July and reaffirms that it expects to attain 50 percent penetration of its installed customer base using the Shiga Toxin Direct Test within five to seven months.

“We are very excited about the market response we’ve received for our Shiga Toxin Direct Test, both from our existing customer base and from brand new opportunities including larger reference laboratories,” said Ryan Ashton, co-founder and chief executive officer of Great Basin Scientific. “We’re further encouraged to discover test volume estimates are proving to be higher than we initially expected, much of which is a result of demand from larger sites for this unique and valuable assay. Existing STEC detection methods vary from extremely expensive to time- consuming and inaccurate. In contrast, Great Basin’s Shiga Toxin Direct Test is easy to use, competitively priced and provides more answers than other stand-alone tests. Further, by placing our analyzer at no cost, we remove the financial barriers previously seen in molecular diagnostics so hospitals and labs of all sizes can provide superior medical and economic value.”

STEC is a leading cause of infections like acute gastroenteritis and hemolytic-uremic syndrome, and the Centers for Disease Control and Prevention (CDC) has stressed the significance of early detection to manage STEC-related infections. Great Basin’s test simplifies the workflow for laboratory technicians, enabling sample-to-result testing with less than one minute of hands-on time using a patient’s preserved stool without overnight enrichment. Great Basin’s Shiga Toxin Direct Test is the only standalone molecular test detecting both Shiga toxin-producing E. coli

and E. coli O157 cleared by the U.S. Food and Drug Administration (FDA). The fully enclosed cartridge assay runs on the Great Basin Analyzer.

“Rapid and accurate identification of STEC in symptomatic patients is essential for optimal disease management,” said Dr. Blake W. Buchan, Assistant Professor of Pathology and Associate Director of Clinical Microbiology at the Medical College of Wisconsin, a clinical trial site for Great Basin’s Shiga Toxin Direct Test. “Unlike other causes of acute gastroenteritis, administration of antibiotics may actually increase the risk of severe complications and is not recommended by the CDC. An inexpensive, rapid molecular test can address the shortcomings of current culture and EIA methods by providing a result in as little as 2 hours without the need for broth enrichment of the stool and multiple additional diagnostic tests. The high sensitivity of molecular tests enables detection of STEC in more specimens, which means more patients get a definitive diagnosis and can be treated appropriately more quickly.”

The Shiga Toxin Direct Test recently received the CE marking designation under the European Directive on In Vitro Diagnostic Medical Devices. It is the third CE marked molecular diagnostic assay designation for Great Basin, following its tests for Group B Streptococcus (GBS) and Clostridium difficile (C. diff).

About Great Basin Scientific

Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company’s website at

Forward-Looking Statements

This press release includes forward-looking statements regarding the Company’s continuing business efforts related to its products, including but not limited to the future market response and acceptance of the Shiga Toxin Direct Test. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses (ii) our ability to develop and commercialize new products and the timing of commercialization (iii) our ability to

obtain capital when needed and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and Quarterly Report on From 10-Q for the quarter ended March 31, 2016. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.

View Post View/Download PDF